#None #Pomerantz LLP #Savara Inc #SVRA

Pomerantz Law Firm Investigates Claims for Savara Investors

On June 7, 2025, Pomerantz LLP announced it is investigating claims on behalf of investors of Savara Inc. (NASDAQ: SVRA). This inquiry follows a dramatic decline in Savara's stock price, which dropped 31.69% on May 27, 2025, when the company disclosed that the FDA had issued a refusal-to-file letter regarding their Biologics License Application for MOLBREEVI, intended to treat patients suffering from autoimmune PAP.

The drop in stock price, amounting to a loss of $0.90 per share, marked a significant impact on investor confidence, prompting Pomerantz to take action. The firm encourages any affected investors to reach out to Danielle Peyton via email at [email protected] or by phone at 646-581-9980, ext. 7980 for further information about joining the class action.

The investigation centers on allegations that Savara and certain officers or directors may have engaged in securities fraud or other unlawful business practices. As investors question the company's transparency and accountability, legal experts from Pomerantz LLP are prepared to delve deeper into the specifics of the case and explore the potential avenues for redress.

Pomerantz LLP has a notable history of handling corporate and securities law cases, having been established by Abraham L. Pomerantz, a significant figure in class action litigation. With over 85 years of experience, the firm has been at the forefront of protecting investor rights, handling breaches of fiduciary duty, and fighting against corporate misconduct. Their past successes include obtaining substantial settlements for victims of securities fraud.

The law firm operates out of various locations, including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, further indicating its wide reach and capability in dealing with complex legal matters. Now, they are focused on the potential repercussions for Savara's investors, examining the facts surrounding the company's stock performance and regulatory challenges, and determining whether there was misinformation or lack of due diligence involved in their business practices.

As the situation develops, Pomerantz's legal team aims to provide insightful guidance to investors who may have suffered losses as a result of the recent incidents. It is also essential for current shareholders of Savara to remain vigilant and informed, as the ongoing investigation might impact future company valuations depending on the outcomes of their findings.

In conclusion, the actions taken by Pomerantz LLP to investigate the claims against Savara Inc. underline the importance of accountability in corporate governance and investor relations. This situation serves as a reminder of the risks involved in investing, and the critical nature of staying informed about the companies in which one invests.

If you are an investor concerned about this matter or wish to share your personal experience with Savara Inc., consider reaching out to the contact provided by Pomerantz LLP. Keeping the lines of communication open is vital in these times as affected individuals gather evidence and support for potential legal actions.